Ignite Creation Date:
2024-05-06 @ 6:06 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05546905
Status:
RECRUITING
Last Update Posted:
2022-09-21
First Post:
2022-06-23
Brief Title:
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer OCTOPUS
Sponsor:
Pierre Fabre Medicament
Organization:
Pierre Fabre Medicament
Study Overview
Official Title:
An Observational Study Describing Diagnosis and Treatment Patterns in Adults With Metastatic Non-small Cell Lung Cancer With BRAF V600E Mutation in Clinical Practice to Assess Treatment Effectiveness and Quality of Life OCTOPUS
Status:
RECRUITING
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to describe the treatment patterns in clinical practice in adult patients with mNSCLC with a BRAF V600E mutation This study will also describe Real-World Progression-Free Survival rwPFS and Overall Survival OS for treatments prescribed in routine practice for mNSCLC with BRAF V600E mutation Adverse events AEs related to treatment management will also be described
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None